Navigation Links
Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
Date:11/2/2012

lated to manufacturing integration.(m) Non cash interest expense associated with amortization of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest totals for the nine months ended September 30, 2012 and September 30, 2011 are $14.2 million and $19.0 million, respectively.(n) Total tax effect of non-GAAP pre-tax adjustments, resolution of uncertain tax positions and change in valuation allowance associated with deferred tax asset. Valeant Pharmaceuticals International, Inc. Table 3 Statement of Revenue - by SegmentFor the Three and Nine Months Ended September 30, 2012 and 2011(In thousands) Three Months Ended September 30,Revenue(a)(b)2012
GAAP2011
GAAP%
Change2012 currency impact2012 excluding currency impact
 non-GAAP%
Change  U.S. Dermatology $
312,449$
33,649134%$
-$
312,449134%  U.S. Neurology & Other180,909180,2810%-180,9090%Canada/Australia 141,07284,64467%1,911142,98369%Emerging Markets249,709202,01024%29,820279,52938%Total Revenue$
884,140
$
,584
47%$  31,731$
915,870
52% Nine Months Ended September 30,Revenue(a)(b)2012
GAAP2011
GAAP%
Change2012 currency impact2012 excluding currency impact
 non-GAAP%
ChangeU.S. Dermatology $
822,714$
399,833106%$
-$
822,714106%U.S. Neurology & Other591,582620,759-5%-591,582-5%Canada/Australia402,001238,88868%6,779408,78071%Emerging Markets744,035515,51744%92,136836,17162%Total Revenue$   2,560,333$  1,774,99744%'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... New York, NY (PRWEB) , ... September 01, ... ... nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving ... patient services – today announced its annual Light it Red for Lymphoma awareness ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Philanthropic giving ... awareness of societal issues and needs. Money for Good 2015, released today by Camber ... it. There’s an annual potential to mobilize up to $22B in new philanthropic giving ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic ... ACE Club and Green Valley Country Club in Lafayette Hill, PA. Over the past ... than $13.5 million for programs and services designed to support patients and their families ...
Breaking Medicine News(10 mins):Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 2Health News:Lymphoma Research Foundation Recognizes National Blood Cancer Awareness Month with Light it Red for Lymphoma Campaign 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... for Fluocinonide Cream 0.1%, a generic version of,VANOS(R) Cream ... to file an,ANDA with a Paragraph IV certification against ... (steroid,hormone) approved to relieve the inflammation and itching caused ...
... rosiglitazone showed 59.5% reduced risk of retina damage , , ... may slow the progression of eye disease in diabetes ... Eye Institute at the University of California, Los Angeles. ... the drug were less likely to develop proliferative diabetic ...
... say it will be several years before there,s widespread ... sophisticated new imaging device could one day help doctors ... earlier and more accurately, researchers report. , If left ... sudden or acute glaucoma attack, which can result in ...
... Results from five pivotal phase 3 studies of ... Association (ADA) 68th Scientific Sessions by Takeda Global ... has been shown to be a highly selective ... investigation as an oral treatment for type 2 ...
... June 9 Today, Earvin "Magic",Johnson ( ... (NYSE: ABT ) and the Magic ... as part of the,"I Stand With Magic ... Black HIV/AIDS,",directed by Academy Award-nominated director Spike ...
... U.S.,Fund for UNICEF and global pharmaceutical company, Merck & ... of M-M-R(R) II,(measles, mumps and rubella virus vaccine, live, ... Moldova, in response to an,ongoing serious mumps outbreak in ... against three diseases, measles,mumps, and rubella, and will be ...
Cached Medicine News:Health News:Perrigo Confirms Filing for Generic Version of VANOS(R) 2Health News:Diabetes Drug May Slow Eye Disease 2Health News:New Imaging Tool Can Spot Glaucoma Risk 2Health News:New Imaging Tool Can Spot Glaucoma Risk 3Health News:Phase 3 results for alogliptin 2Health News:Phase 3 results for alogliptin 3Health News:Now Playing: Spike Lee Stands with Earvin 'Magic' Johnson, Cookie Johnson and Abbott to Launch National PSA Campaign 2Health News:Now Playing: Spike Lee Stands with Earvin 'Magic' Johnson, Cookie Johnson and Abbott to Launch National PSA Campaign 3Health News:Now Playing: Spike Lee Stands with Earvin 'Magic' Johnson, Cookie Johnson and Abbott to Launch National PSA Campaign 4Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 2Health News:UNICEF & Merck Partner to Protect 100,000 Children and Young People Against Mumps Epidemic 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: